Ultrasound assisted transdermal vaccine delivery method and system

• US 20050112135A1
• Filed: 10/21/2004
• Published: 05/26/2005
• Est. Priority Date: 11/21/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Widera, Georg, Cormier, Michel J.N., Lin, WeiQi
• Application Number:
  US10/971,338
• Publication Number:
  US 20050112135A1
• Time in Patent Office: Days
• US Class Current: 424/185.100
• CPC Class Codes: A61B 17/205 Vaccinating by means of needles or other puncturing devices
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/292 Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61M 37/0092 using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C12N 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

An apparatus and method for transdermally delivering a vaccine comprising a delivery system having (i) a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers and (ii) an ultrasonic device. In one embodiment, the vaccine is contained in a biocompatible coating that is applied to the microprojection member. In a further embodiment, the delivery system includes a gel pack having a vaccine-containing hydrogel formulation that is disposed on the microprojection member after application to the skin of a patient. In an alternative embodiment, the vaccine is contained in both the coating and the hydrogel formulation.

Claims

1. A delivery system for delivering an immunologically active agent to a subject, comprising:

a microprojection member having a plurality of stratum corneum-piercing microprojections;

a formulation having said immunologically active agent; and

an ultrasonic device adapted to apply ultrasonic energy to said subject.

2. The system of claim 1, wherein said microprojection member has a microprojection density of at least approximately 10 microprojections/cm².

3. The system of claim 2, wherein said microprojection member has a microprojection density in the range of at least approximately 200-2000 microprojections/cm² .

4. The system of claim 1, wherein said microprojections are adapted to pierce through the stratum corneum to a depth of less than about 500 micrometers.

5. The system of claim 1, wherein said formulation comprises a coating disposed on at least one of said microprojections.

6. The system of claim 1, wherein said immunologically active agent comprises a protein-based vaccine.

7. The system of claim 6, wherein said application of said ultrasonic energy to said subject provides in vivo intracellular delivery of said protein-based vaccine, whereby said delivery of said protein-based vaccine into skin-presenting cells leads to cellular loading of said protein-based vaccine onto class I MHC/HLA presentation molecules in addition to class II MHC/HLA presentation molecules.

8. The system of claim 7, wherein a cellular and humoral response is produced in said subject

9. The system of claim 1, wherein said immunologically active agent comprises a DNA vaccine.

10. The system of claim 9, wherein said application of said ultrasonic energy to said subject provides in vivo intracellular delivery of said DNA vaccine, whereby said delivery of said DNA vaccine leads to cellular expression of protein and loading of said protein onto class I MHC/HLA presentation molecules in addition to class II MHC/HLA presentation molecules.

11. The system of claim 10, wherein a cellular and humoral response is produced in said subject

12. The system of claim 10, wherein said immune response produced in said subject is exclusively a cellular response

13. The system of claim 1, wherein said immunologically active agent comprises an agent selected from the group consisting of proteins, polysaccharide conjugates, oligosaccharides, lipoproteins, subunit vaccines, Bordetella pertussis (recombinant DPT vaccine—

acellular), Clostridium tetani (purified, recombinant), Corynebacterium diptheriae (purified, recombinant), Cytomegalovirus (glycoprotein subunit), Group A streptococcus (glycoprotein subunit, glycoconjugate Group A polysaccharide with tetanus toxoid, M protein/peptides linked to toxing subunit carriers, M protein, multivalent type-specific epitopes, cysteine protease, C5a peptidase), Hepatitis B virus (recombinant Pre S1, Pre-S2, S, recombinant core protein), Hepatitis C virus (recombinant—

expressed surface proteins and epitopes), Human papillomavirus (Capsid protein, TA-GN recombinant protein L2 and E7 [from HPV-6], MEDI-501 recombinant VLP L1 from HPV-1 1, Quadrivalent recombinant BLP L1 [from HPV-6], HPV-1 1, HPV-16, and HPV-18, LAMP-E7 [from HPV-16]), Legionella pneumophila (purified bacterial surface protein), Neisseria meningitides (glycoconjugate with tetanus toxoid), Pseudomonas aeruginosa (synthetic peptides), Rubella virus (synthetic peptide), Streptococcus pneumoniae (glyconconjugate [1, 4, 5, 6B, 9N, 14, 18C, 19V, 23F] conjugated to meningococcal B OMP, glycoconjugate [4, 6B, 9V, 14, 18C, 19F, 23F] conjugated to CRM197, glycoconjugate [1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F] conjugated to CRM 1970, Treponema pallidum (surface lipoproteins), Varicella zoster virus (subunit, glycoproteins), Vibrio cholerae (conjugate lipopolysaccharide), whole virus, bacteria, weakened or killed viruses, cytomegalo virus, hepatitis B virus, hepatitis C virus, human papillomavirus, rubella virus, varicella zoster, weakened or killed bacteria, bordetella pertussis, clostridium tetani, corynebacterium diptheriae, group A streptococcus, legionella pneumophila, neisseria meningitis, pseudomonas aeruginosa, streptococcus pneumoniae, treponema pallidum, vibrio cholerae, flu vaccines, Lyme disease vaccine, rabies vaccine, measles vaccine, mumps vaccine, chicken pox vaccine, small pox vaccine, hepatitis vaccine, pertussis vaccine, diptheria vaccine, nucleic acids, single-stranded and double-stranded nucleic acids, supercoiled plasmid DNA, linear plasmid DNA, cosmids, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), mammalian artificial chromosomes, and RNA molecules.

14. The system of claim 13, wherein said formulation includes an immunologically potentiating adjuvant.

15. The system of claim 14, wherein said adjuvant is selected from the group consisting of aluminum phosphate gel, aluminum hydroxide, algal glucan, b-glucan, cholera toxin B subunit, CRL1005, ABA block polymer with mean values of x=8 and y=205, gamma insulin, linear (unbranched) β

-D(2->

1) polyfructofuranoxyl-a-D-glucose, Gerbu adjuvant, N-acetylglucosamine-(b 1-4)-N-acetylmuramyl-L-alanyl-D-glutamine (GMDP), dimethyl dioctadecylammonium chloride (DDA), zinc L-proline salt complex (Zn-Pro-8), Imiquimod (1-(2-methypropyl)-1 H-imidazo[4,5-c]quinolin-4-amine, ImmTher™

, N-acetylglucoaminyl-N-acetylmuramyl-L-Ala-D-isoGlu-L-Ala-glycerol dipalmitate, MTP-PE liposomes, C59H108N6O19PNa—

3H2O (MTP), Murametide, Nac-Mur-L-Ala-D-Gln-OCH3, Pleuran, b-glucan, QS-21;

S-28463, 4-amino-a, a-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, sclavo peptide, VQGEESNDK.HCl (1L-1b 163-171 peptide), threonyl-MDP (Termurtide™

), N-acetyl muramyl-L-threonyl-D-isoglutamine, interleukin 18, IL-2 IL-12, IL-15, DNA oligonucleotides, CpG containing oligonucleotides, gamma interferon, NF kappa B regulatory signaling proteins, heat-shock proteins (HSPs), GTP-GDP, Loxoribine, MPL®

, Murapalmitine, and Theramide™

.

16. The system of claim 5, wherein said formulation includes a surfactant.

17. The system of claim 16, wherein said surfactant is selected from the group consisting of sodium lauroamphoacetate, sodium dodecyl sulfate (SDS), cetylpyridinium chloride (CPC), dodecyltrimethyl ammonium chloride (TMAC), benzalkonium, chloride, polysorbates, such as Tween 20 and Tween 80, sorbitan derivatives, sorbitan laureate, alkoxylated alcohols, and laureth-4.

18. The system of claim 5, wherein said formulation includes an amphiphilic polymer.

19. The system of claim 18, wherein said amphiphilic polymer is selected from the group consisting of cellulose derivatives, hydroxyethylcellulose (HEC), hydroxypropyl-methylcellulose (HPMC), hydroxypropycellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), ethylhydroxyethylcellulose (EHEC), and pluronics.

20. The system of claim 5, wherein said formulation includes a hydrophilic polymer.

21. The system of claim 20, wherein said hydrophilic polymer is selected from the group consisting of poly(vinyl alcohol), poly(ethylene oxide), poly(2-hydroxyethylmethacrylate), poly(n-vinyl pyrolidone), polyethylene glycol and mixtures thereof.

22. The system of claim 5, wherein said formulation includes a biocompatible carrier.

23. The system of claim 22, wherein said biocompatible polymer is selected from the group consisting of human albumin, bioengineered human albumin, polyglutamic acid, polyaspartic acid, polyhistidine, pentosan polysulfate, polyamino acids, sucrose, trehalose, melezitose, raffinose and stachyose.

24. The system of claim 5, wherein said formulation includes a vasoconstrictor.

25. The system of claim 24, wherein said vasoconstrictor is selected from the group consisting of epinephrine, naphazoline, tetrahydrozoline indanazoline, metizoline, tramazoline, tymazoline, oxymetazoline, xylometazoline, amidephrine, cafaminol, cyclopentamine, deoxyepinephrine, epinephrine, felypressin, indanazoline, metizoline, midodrine, naphazoline, nordefrin, octodrine, ornipressin, oxymethazoline, phenylephrine, phenylethanolamine, phenylpropanolamine, propylhexedrine, pseudoephedrine, tetrahydrozoline, tramazoline, tuaminoheptane, tymazoline, vasopressin and xylometazoline.

26. The system of claim 5, wherein said formulation includes a pathway patency modulator.

27. The system of claim 26, wherein said pathway patency modulator is selected from the group consisting of osmotic agents, sodium chloride, zwitterionic compounds, amino acids, anti-inflammatory agents, betamethasone 21-phosphate disodium salt, triamcinolone acetonide 21-disodium phosphate, hydrocortamate hydrochloride, hydrocortisone 21-phosphate disodium salt, methylprednisolone 21-phosphate disodium salt, methylprednisolone 21-succinaate sodium salt, paramethasone disodium phosphate, prednisolone 21-succinate sodium salt, anticoagulants, citric acid, citrate salts, sodium citrate, dextran sulfate sodium, and EDTA.

28. The system of claim 5, wherein said formulation includes an antioxidant.

29. The system of claim 28, wherein said antioxidant is selected from the group consisting of sodium citrate, citric acid, ethylene-dinitrilo-tetraacetic acid (EDTA), ascorbic acid, methionine, and sodium ascorbate.

30. The system of claim 5, wherein said formulation further includes a low volatility counterion.

31. The system of claim 30, wherein said low volatility counterion is selected from the group consisting of maleic acid, malic acid, malonic acid, tartaric acid, adipic acid, citraconic acid, fumaric acid, glutaric acid, itaconic acid, meglutol, mesaconic acid, succinic acid, citramalic acid, tartronic acid, citric acid, tricarballylic acid, ethylenediaminetetraacetic acid, aspartic acid, glutamic acid, carbonic acid, sulfuric acid, and phosphoric acid, and mixtures thereof.

32. The system of claim 30, wherein said low volatility counterion is selected from the group consisting of monoethanolomine, diethanolamine, triethanolamine, tromethamine, methylglucamine, glucosamine, histidine, lysine, arginine, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonia and morpholine, and mixtures thereof.

33. The system of claim 5, wherein said coating has a viscosity less than approximately 500 centipoise and greater than 3 centipoise.

34. The system of claim 5, wherein said coating has a thickness less than approximately 25 microns.

35. The system of claim 1, wherein said formulation comprises a hydrogel.

36. The system of claim 35, wherein said hydrogel comprises a macromolecular polymeric network.

37. The system of claim 36, wherein said macromolecular polymeric network is selected from the group consisting of hydroxyethylcellulose (HEC), hydroxypropylmethylcellulose (HPMC), hydroxypropycellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), ethylhydroxyethylcellulose (EHEC), carboxymethyl cellulose (CMC), poly(vinyl alcohol), poly(ethylene oxide), poly(2-hydroxyethylmethacrylate), poly(n-vinyl pyrolidone), and pluronics.

38. The system of claim 35, wherein said formulation includes a surfactant.

39. The system of claim 38, wherein said surfactant is selected from the group consisting of sodium lauroamphoacetate, sodium dodecyl sulfate (SDS), cetylpyridinium chloride (CPC), dodecyltrimethyl ammonium chloride (TMAC), benzalkonium, chloride, polysorbates, such as Tween 20 and Tween 80, sorbitan derivatives, sorbitan laureate, alkoxylated alcohols, and laureth-4.

40. The system of claim 35, wherein said formulation includes an amphiphilic polymer.

41. The system of claim 40, wherein said amphiphilic polymer is selected from the group consisting of cellulose derivatives, hydroxyethylcellulose (HEC), hydroxypropyl-methylcellulose (HPMC), hydroxypropycellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), ethylhydroxyethylcellulose (EHEC), and pluronics.

42. The system of claim 35, wherein said formulation includes a pathway patency modulator.

43. The system of claim 42, wherein said pathway patency modulator is selected from the group consisting of osmotic agents, sodium chloride, zwitterionic compounds, amino acids, anti-inflammatory agents, betamethasone 21-phosphate disodium salt, triamcinolone acetonide 21-disodium phosphate, hydrocortamate hydrochloride, hydrocortisone 21-phosphate disodium salt, methylprednisolone 21-phosphate disodium salt, methylprednisolone 21-succinaate sodium salt, paramethasone disodium phosphate, prednisolone 21-succinate sodium salt, anticoagulants, citric acid, citrate salts, sodium citrate, dextran sulfate sodium, and EDTA.

44. The system of claim 35, wherein said formulation includes a vasoconstrictor.

45. The system of claim 44, wherein said vasoconstrictor is selected from the group consisting of epinephrine, naphazoline, tetrahydrozoline indanazoline, metizoline, tramazoline, tymazoline, oxymetazoline, xylometazoline, amidephrine, cafaminol, cyclopentamine, deoxyepinephrine, epinephrine, felypressin, indanazoline, metizoline, midodrine, naphazoline, nordefrin, octodrine, omipressin, oxymethazoline, phenylephrine, phenylethanolamine, phenylpropanolamine, propylhexedrine, pseudoephedrine, tetrahydrozoline, tramazoline, tuaminoheptane, tymazoline, vasopressin and xylometazoline.

46. The system of claim 1, wherein said ultrasonic device is adhered to said microprojection member.

47. The system of claim 1, wherein said ultrasonic device further includes a matching layer to facilitate transmission of said ultrasonic energy.

48. The system of claim 47, wherein said ultrasonic device further includes a double-sided adhesive layer.

49. The system of claim 1, wherein said ultrasonic device generates sound waves having a frequency at least about 20 kHz.

50. A method for transdermally delivering an immunologically active agent to a subject, comprising the steps of:

providing a microprojection delivery system, said delivery system including a microprojection member having a plurality of stratum corneum-piercing microprojections, a formulation including the immunologically active agent and an ultrasonic device;

applying said microprojection member to a desired location on said subject; and

transmitting ultrasonic energy from said ultrasonic device to said desired location on said subject to facilitate delivery of said immunologically active agent.

51. The method of claim 50, wherein said immunologically active agent comprises protein-based vaccines.

52. The method of claim 51, wherein said transmission of said ultrasonic energy to said subject provides in vivo intracellular delivery of said protein-based vaccine, whereby said delivery of said protein-based vaccine into skin-presenting cells leads to cellular loading of said protein-based vaccine onto class I MHC/HLA presentation molecules in addition to class II MHC/HLA presentation molecules.

53. The method of claim 52, wherein a cellular and humoral response is produced in said subject.

54. The method of claim 50, wherein said immunologically active agent comprises a DNA vaccine.

55. The method of claim 54, wherein said transmission of said ultrasonic energy to said subject provides in vivo intracellular delivery of said DNA vaccine, whereby said delivery of said DNA vaccine leads to cellular expression of protein and loading of said protein onto class I MHC/HLA presentation molecules in addition to class II MHC/HLA presentation molecules.

56. The method of claim 55, wherein a cellular and humoral response is produced in said subject.

57. The method of claim 55, wherein said immune response produced in said subject is exclusively a cellular response.

58. The method of claim 50, wherein said step of transmitting ultrasonic energy from said ultrasonic device comprises directing said ultrasonic energy through said microprojection member.

59. The method of claim 58, wherein said ultrasonic device is adhered to said microprojection member.

60. The method of claim 58, wherein said formulation comprises a hydrogel incorporated in a gel pack and wherein said ultrasonic device is adhered to said gel pack.

61. The method of claim 50, further comprising the step of removing said microprojection member before transmitting energy with said ultrasonic device.

62. The method of claim 61, wherein said step of transmitting ultrasonic energy with said ultrasonic device includes the step of adhering said ultrasonic device to said desired location on said subject.

63. The method of claim 50, wherein said formulation comprises a coating applied to at least one of said microprojections and wherein said step of transmitting said ultrasonic energy with said ultrasonic device occurs in the range of approximately 5 sec to 30 min after said step of applying said microprojection member to said subject.

64. The method of claim 50, wherein said step of transmitting ultrasonic energy with said ultrasonic device occurs in the range of approximately 30 sec to 15 min after said step of applying said microprojection member to said subject.

65. The method of claim 50, wherein said formulation comprises a hydrogel incorporated in a gel pack and wherein said step of transmitting ultrasonic energy with said ultrasonic device occurs in the range of approximately 5 min to 24 h after said step of applying said microprojection member to said subject.

66. The method of claim 65, wherein said step of transmitting ultrasonic energy with said ultrasonic device occurs in the range of approximately 10 min to 4 h after said step of applying said microprojection member to said subject.

67. The method of claim 50, wherein said formulation comprises a coating applied to at least one of said microprojections and a hydrogel incorporated in a gel pack.

68. The method of claim 67, further including the step of removing said microprojection member from said subject before said step of transmitting said ultrasonic energy to said subject.

69. The method of claim 67, wherein said step of transmitting energy with said ultrasonic device occurs in the range of approximately 5 sec to 24 h after said step of applying said microprojection member to said subject.

70. The method of claim 67, wherein said step of transmitting ultrasonic energy with said ultrasonic device occurs in the range of approximately 30 sec to 4 h after said step of applying said microprojection member to said subject.

71. The method of claim 50, wherein said step of transmitting ultrasonic energy comprises applying sound waves having a frequency in the range of approximately 20 kHz to 10 MHz.

72. The method of claim 67, wherein said step of transmitting ultrasonic energy comprises applying sound waves having a frequency in the range of approximately 20 kHz to 1 MHz.

73. The method of claim 50, wherein said step of transmitting ultrasonic energy comprises applying ultrasonic energy having an intensity in the range of approximately 0.01 W/cm² to 100 W/cm².

74. The method of claim 50, wherein said step of transmitting ultrasonic energy comprises applying ultrasonic energy having an intensity in the range of approximately 1 W/cm² to 20 W/cm².

75. The method of claim 50, wherein said step of transmitting ultrasonic energy comprises applying ultrasonic energy for a duration in the range of approximately 5 sec to 1 h.

76. The method of claim 50, wherein said step of transmitting ultrasonic energy comprises applying energy for a duration in the range of approximately 30 sec to 10 min.